Transcatheter Aortic Valve Replacement for Aortic Insufficiency

Area of Science:

• Cardiology
• Interventional Cardiology
• Biomedical Engineering

Background:

• Transcatheter aortic valve replacement (TAVR) is a key treatment for aortic regurgitation (AR), especially in high-risk patients.
• Early TAVR devices faced challenges like high mortality and paravalvular leaks.
• Technological advancements have significantly improved TAVR procedural outcomes.

Purpose of the Study:

• To review the evolution and current state of TAVR for aortic regurgitation.
• To highlight advancements in TAVR technology for AR treatment.
• To discuss the potential of dedicated and novel devices for complex AR cases.

Main Methods:

• Review of current literature on TAVR for AR.
• Analysis of outcomes associated with early and advanced TAVR devices.
• Evaluation of specific TAVR systems designed for AR.

Main Results:

• Advancements in self-expanding and balloon-expandable TAVR devices have enhanced procedural success.
• Dedicated AR devices like Trilogy and J-Valve demonstrate superior performance and survival rates.
• Emerging systems show promise for treating complex AR, including non-calcified valves and endocarditis.

Conclusions:

• Modern TAVR technology provides effective treatment options for severe aortic regurgitation.
• Dedicated devices and innovative systems are improving outcomes for AR patients.
• Tailored TAVR approaches based on patient-specific anatomy and pathology are crucial for optimal results.